FibroGen Inc. (NASDAQ:FGEN) VP Pat Cotroneo sold 2,345 shares of the firm’s stock in a transaction that occurred on Monday, September 12th. The shares were sold at an average price of $18.22, for a total transaction of $42,725.90. Following the transaction, the vice president now owns 134,359 shares in the company, valued at approximately $2,448,020.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Shares of FibroGen Inc. (NASDAQ:FGEN) opened at 20.10 on Monday. FibroGen Inc. has a one year low of $14.38 and a one year high of $31.90. The company’s 50-day moving average is $18.68 and its 200-day moving average is $18.36. The company’s market capitalization is $1.26 billion.
FibroGen (NASDAQ:FGEN) last issued its earnings results on Monday, August 8th. The biopharmaceutical company reported $0.35 earnings per share for the quarter, missing the consensus estimate of $0.36 by $0.01. FibroGen had a negative net margin of 61.90% and a negative return on equity of 48.66%. Equities analysts predict that FibroGen Inc. will post ($1.25) earnings per share for the current year.
Separately, Credit Suisse Group AG reiterated a “buy” rating and set a $37.00 price objective on shares of FibroGen in a research note on Tuesday, August 9th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $33.25.
Hedge funds have recently modified their holdings of the stock. Acadian Asset Management LLC acquired a new stake in shares of FibroGen during the second quarter valued at $106,000. Acrospire Investment Management LLC raised its position in FibroGen by 240.2% in the second quarter. Acrospire Investment Management LLC now owns 6,657 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 4,700 shares during the period. Teacher Retirement System of Texas raised its position in FibroGen by 15.7% in the second quarter. Teacher Retirement System of Texas now owns 6,891 shares of the biopharmaceutical company’s stock worth $113,000 after buying an additional 937 shares during the period. Quantbot Technologies LP purchased a new position in FibroGen during the second quarter worth approximately $164,000. Finally, Fox Run Management L.L.C. purchased a new position in FibroGen during the second quarter worth approximately $176,000. Institutional investors and hedge funds own 49.82% of the company’s stock.
FibroGen, Inc is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.
Receive News & Ratings for FibroGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.